vs
DULUTH HOLDINGS INC.（DLTH）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是DULUTH HOLDINGS INC.的1.8倍（$207.3M vs $114.9M），DULUTH HOLDINGS INC.净利率更高（-8.8% vs -62.0%，领先53.2%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -9.6%），DULUTH HOLDINGS INC.自由现金流更多（$-8.9M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -31.6%）
德卢思控股是一家美国工装及配饰企业，主打通过旗下德卢思贸易品牌开展产品销售业务，面向市场推出各类实用工装及相关配饰产品，是美国本土颇具特色的服饰零售企业。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
DLTH vs RARE — 直观对比
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $114.9M | $207.3M |
| 净利润 | $-10.1M | $-128.6M |
| 毛利率 | 53.8% | — |
| 营业利润率 | -7.7% | -54.7% |
| 净利率 | -8.8% | -62.0% |
| 营收同比 | -9.6% | 25.9% |
| 净利润同比 | 64.6% | 3.5% |
| 每股收益（稀释后） | $-0.29 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $114.9M | $207.3M | ||
| Q3 25 | $131.7M | $159.9M | ||
| Q2 25 | $102.7M | $166.5M | ||
| Q1 25 | $241.3M | $139.3M | ||
| Q4 24 | $127.1M | $164.6M | ||
| Q3 24 | $141.6M | $139.5M | ||
| Q2 24 | $116.7M | $147.0M | ||
| Q1 24 | $245.6M | $108.8M |
| Q4 25 | $-10.1M | $-128.6M | ||
| Q3 25 | $1.3M | $-180.4M | ||
| Q2 25 | $-15.3M | $-115.0M | ||
| Q1 25 | $-5.6M | $-151.1M | ||
| Q4 24 | $-28.2M | $-133.2M | ||
| Q3 24 | $-2.0M | $-133.5M | ||
| Q2 24 | $-7.9M | $-131.6M | ||
| Q1 24 | $6.4M | $-170.7M |
| Q4 25 | 53.8% | — | ||
| Q3 25 | 54.7% | — | ||
| Q2 25 | 52.0% | — | ||
| Q1 25 | 44.1% | — | ||
| Q4 24 | 52.3% | — | ||
| Q3 24 | 52.3% | — | ||
| Q2 24 | 52.8% | — | ||
| Q1 24 | 48.2% | — |
| Q4 25 | -7.7% | -54.7% | ||
| Q3 25 | 1.8% | -106.9% | ||
| Q2 25 | -12.0% | -64.8% | ||
| Q1 25 | -1.8% | -102.6% | ||
| Q4 24 | -17.4% | -74.3% | ||
| Q3 24 | -1.1% | -94.6% | ||
| Q2 24 | -7.7% | -79.1% | ||
| Q1 24 | 3.6% | -151.9% |
| Q4 25 | -8.8% | -62.0% | ||
| Q3 25 | 1.0% | -112.8% | ||
| Q2 25 | -14.9% | -69.0% | ||
| Q1 25 | -2.3% | -108.5% | ||
| Q4 24 | -22.2% | -80.9% | ||
| Q3 24 | -1.4% | -95.7% | ||
| Q2 24 | -6.7% | -89.5% | ||
| Q1 24 | 2.6% | -156.8% |
| Q4 25 | $-0.29 | $-1.28 | ||
| Q3 25 | $0.04 | $-1.81 | ||
| Q2 25 | $-0.45 | $-1.17 | ||
| Q1 25 | $-0.17 | $-1.57 | ||
| Q4 24 | $-0.84 | $-1.34 | ||
| Q3 24 | $-0.06 | $-1.40 | ||
| Q2 24 | $-0.24 | $-1.52 | ||
| Q1 24 | $0.20 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.2M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $160.6M | $-80.0M |
| 总资产 | $468.0M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $8.2M | $421.0M | ||
| Q3 25 | $5.7M | $202.5M | ||
| Q2 25 | $8.6M | $176.3M | ||
| Q1 25 | $3.3M | $127.1M | ||
| Q4 24 | $9.3M | $174.0M | ||
| Q3 24 | $9.8M | $150.6M | ||
| Q2 24 | $6.8M | $480.7M | ||
| Q1 24 | $32.2M | $112.3M |
| Q4 25 | $160.6M | $-80.0M | ||
| Q3 25 | $170.0M | $9.2M | ||
| Q2 25 | $167.9M | $151.3M | ||
| Q1 25 | $182.7M | $144.2M | ||
| Q4 24 | $188.1M | $255.0M | ||
| Q3 24 | $215.7M | $346.8M | ||
| Q2 24 | $218.4M | $432.4M | ||
| Q1 24 | $222.8M | $140.3M |
| Q4 25 | $468.0M | $1.5B | ||
| Q3 25 | $433.8M | $1.2B | ||
| Q2 25 | $463.7M | $1.3B | ||
| Q1 25 | $452.4M | $1.3B | ||
| Q4 24 | $533.1M | $1.5B | ||
| Q3 24 | $488.6M | $1.5B | ||
| Q2 24 | $471.4M | $1.6B | ||
| Q1 24 | $491.2M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.7M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-8.9M | $-100.8M |
| 自由现金流率自由现金流/营收 | -7.8% | -48.6% |
| 资本支出强度资本支出/营收 | 2.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $1.7M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-6.7M | $-99.8M | ||
| Q3 25 | $32.0M | $-91.4M | ||
| Q2 25 | $-56.5M | $-108.3M | ||
| Q1 25 | $41.2M | $-166.5M | ||
| Q4 24 | $-41.1M | $-79.3M | ||
| Q3 24 | $16.6M | $-67.0M | ||
| Q2 24 | $-33.7M | $-77.0M | ||
| Q1 24 | $69.7M | $-190.7M |
| Q4 25 | $-8.9M | $-100.8M | ||
| Q3 25 | $29.8M | $-92.7M | ||
| Q2 25 | $-57.8M | $-110.7M | ||
| Q1 25 | $38.7M | $-167.8M | ||
| Q4 24 | $-43.7M | $-79.5M | ||
| Q3 24 | $15.0M | $-68.6M | ||
| Q2 24 | $-35.2M | $-79.0M | ||
| Q1 24 | $60.6M | $-193.9M |
| Q4 25 | -7.8% | -48.6% | ||
| Q3 25 | 22.6% | -58.0% | ||
| Q2 25 | -56.3% | -66.5% | ||
| Q1 25 | 16.0% | -120.5% | ||
| Q4 24 | -34.4% | -48.3% | ||
| Q3 24 | 10.6% | -49.2% | ||
| Q2 24 | -30.2% | -53.7% | ||
| Q1 24 | 24.7% | -178.2% |
| Q4 25 | 2.0% | 0.5% | ||
| Q3 25 | 1.7% | 0.8% | ||
| Q2 25 | 1.3% | 1.5% | ||
| Q1 25 | 1.0% | 1.0% | ||
| Q4 24 | 2.1% | 0.1% | ||
| Q3 24 | 1.2% | 1.2% | ||
| Q2 24 | 1.3% | 1.4% | ||
| Q1 24 | 3.7% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | 25.40× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 10.86× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DLTH
| Sales Channel Directly To Consumer | $67.4M | 59% |
| Sales Channel Through Intermediary | $47.4M | 41% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
